These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27671971)

  • 1. Effect of glycation inhibitors on aging and age-related diseases.
    Sadowska-Bartosz I; Bartosz G
    Mech Ageing Dev; 2016 Dec; 160():1-18. PubMed ID: 27671971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation endproducts in ageing and Alzheimer's disease.
    Münch G; Thome J; Foley P; Schinzel R; Riederer P
    Brain Res Brain Res Rev; 1997 Feb; 23(1-2):134-43. PubMed ID: 9063589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycation in Parkinson's disease and Alzheimer's disease.
    Vicente Miranda H; El-Agnaf OM; Outeiro TF
    Mov Disord; 2016 Jun; 31(6):782-90. PubMed ID: 26946341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
    Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
    Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
    Yamagishi S; Taguchi K; Fukami K
    Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.
    Salahuddin P; Rabbani G; Khan RH
    Cell Mol Biol Lett; 2014 Sep; 19(3):407-37. PubMed ID: 25141979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic targeting of advanced glycation end-products in age-related diseases.
    Rowan S; Bejarano E; Taylor A
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3631-3643. PubMed ID: 30279139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathways of the Maillard reaction under physiological conditions.
    Henning C; Glomb MA
    Glycoconj J; 2016 Aug; 33(4):499-512. PubMed ID: 27291759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease.
    Pugazhenthi S; Qin L; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2017 May; 1863(5):1037-1045. PubMed ID: 27156888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
    Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
    Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease.
    Sato T; Shimogaito N; Wu X; Kikuchi S; Yamagishi S; Takeuchi M
    Am J Alzheimers Dis Other Demen; 2006; 21(3):197-208. PubMed ID: 16869341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis and review examining a possible role for oxidative stress and singlet oxygen in diverse diseases.
    Petrou AL; Terzidaki A
    Biochem J; 2017 Aug; 474(16):2713-2731. PubMed ID: 28768713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease.
    Shuvaev VV; Laffont I; Serot JM; Fujii J; Taniguchi N; Siest G
    Neurobiol Aging; 2001; 22(3):397-402. PubMed ID: 11378244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective.
    Li J; Liu D; Sun L; Lu Y; Zhang Z
    J Neurol Sci; 2012 Jun; 317(1-2):1-5. PubMed ID: 22410257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers.
    Nicholl ID; Stitt AW; Moore JE; Ritchie AJ; Archer DB; Bucala R
    Mol Med; 1998 Sep; 4(9):594-601. PubMed ID: 9848076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Methodologies to Study the Role of Advanced Glycation End Products (AGEs) in Neurodegeneration.
    Chrysanthou M; Miro Estruch I; Rietjens IMCM; Wichers HJ; Hoppenbrouwers T
    Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iridoids are natural glycation inhibitors.
    West BJ; Deng S; Uwaya A; Isami F; Abe Y; Yamagishi S; Jensen CJ
    Glycoconj J; 2016 Aug; 33(4):671-81. PubMed ID: 27306206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation in diabetes, aging and age-related diseases: conclusions.
    Monnier VM; Taniguchi N
    Glycoconj J; 2016 Aug; 33(4):691-2. PubMed ID: 27421862
    [No Abstract]   [Full Text] [Related]  

  • 19. Dietary advanced glycation end products and aging.
    Luevano-Contreras C; Chapman-Novakofski K
    Nutrients; 2010 Dec; 2(12):1247-65. PubMed ID: 22254007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced Glycation End Products in Chinese Medicine Mediated Aging Diseases: A Review.
    Zhang W; Zhao T; Zhao Y; Gui D; Xu Y
    Curr Vasc Pharmacol; 2020; 18(4):322-333. PubMed ID: 31060489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.